HRT Financial’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-56,624
Closed -$3.46M – 5946
2026
Q2
$3.22M Sell
56,624
-116,988
-67% -$5.19M 0.01% 1427
2026
Q1
$5.16M Buy
+173,612
New +$5.19M 0.01% 991
2025
Q2
– Sell
-49,371
Closed -$884K – 3535
2025
Q1
$884K Buy
49,371
+34,966
+243% +$710K 0.01% 1161
2024
Q4
$250K Sell
14,405
-93,087
-87% -$1.65M ﹤0.01% 1825
2024
Q3
$1.5M Buy
107,492
+16,028
+18% +$167K 0.01% 1013
2024
Q2
$751K Buy
+91,464
New +$616K ﹤0.01% 1128
2024
Q1
– Sell
-148,943
Closed -$1.34M – 3111
2023
Q4
$1.34M Buy
148,943
+33,626
+29% +$245K 0.01% 850
2023
Q3
$1.03M Buy
+115,317
New +$1.63M 0.01% 953
2023
Q2
– Sell
-17,909
Closed -$402K – 3292
2023
Q1
$402K Buy
+17,909
New +$381K ﹤0.01% 1538
2022
Q2
– Sell
-74,002
Closed -$1.91M – 3739
2022
Q1
$1.91M Buy
+74,002
New +$1.96M 0.01% 662
2021
Q4
– Sell
-72,215
Closed -$1.75M – 4097
2021
Q3
$1.75M Buy
+72,215
New +$1.33M 0.01% 831
2020
Q1
– Sell
-16,595
Closed -$235K – 1365
2019
Q4
$235K Buy
+16,595
New +$212K 0.01% 867

Other funds holding TVTX

HRT Financial's TVTX Position: Q3 2026 in Review

HRT Financial sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 56,624 shares — an estimated $3.46M sold.

HRT Financial first reported a position in TVTX in Q4 2019 and held it in 12 quarters. The position peaked at $5.16M in Q1 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • HRT Financial reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
  • HRT Financial sold 56,624 Travere Therapeutics shares in Q3 2026, an estimated $3.46M.
  • HRT Financial first reported a position in Travere Therapeutics in Q4 2019 and held it in 12 quarters.
  • HRT Financial's Travere Therapeutics position peaked at $5.16M in Q1 2026.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.